NEX-I, First-In-Class Cancer Immunotherapy Development Company
At NEX-I, we craft pioneering treatments with a singular goal: enhancing patients' lives and bringing comfort to their families.
NEX-I drives a paradigm shift from the current regimen of standard of care in anti-cancer therapies to provide new clinical values.
Leveraging our next-generation discovery platform, NEX-I thoroughly crafts assessment tools, ensuring pinpoint accuracy in evaluating the efficacy of First-In-Class cancer immunotherapy.